Amid swirling speculation, Bausch + Lomb ($BLCO), a global leader in the contact lens supply industry, is reportedly ...

It isn't known whether Bausch + Lomb and/or Goldman is in contact with either Blackstone or TPG. According to the FT, several private equity funds mulling offers have dropped out of the race.

Private equity groups TPG and Blackstone have teamed up to work on a joint bid for eyecare company Bausch + Lomb, according ... which comes from sales of contact lenses and dry eye drugs Xiidra ...

Bausch & Lomb is one of the largest vision ... materials and may not be compatible with newer contact lenses. Branded products like Bausch’s Biotrue hydration plus multi-purpose solution ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) yesterday and set a ...

including Biotrue and SofLens. We are still impressed at the overall performance and believe the firm's share in the contact lens market slightly increased. Miebo and Xiidra, Bausch & Lomb's dry ...

Eye health firm Bausch + Lomb has received marketing approval for its full range of enVista Envy vision intraocular lenses (IOL) from the US Food and Drug Administration (FDA). Following the ...

STAT gathered reactions from leaders across biotech and pharma about what the new Trump era could mean for them.

Bausch + Lomb is also in the process of seeking regulatory approvals for the lens in additional markets. The enVista Envy hydrophobic acrylic IOL is indicated for primary implantation in the capsular ...

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) today and set a price ...